Ibrutinib improves survival for relapsed or refractory chronic lymphocytic leukemia (CLL) after first-line chemoimmunotherapy: population-based outcomes from 677 patients treated in British Columbia (BC)
LEUKEMIA & LYMPHOMA（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要